A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome (NCT06118255)

🧪 Interventions in This Study

• fenfluramine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (12 Sites)

• Ep0213 105 — Memphis, Tennessee
• Ep0213 107 — Dallas, Texas
• Ep0213 103 — Seattle, Washington
• Ep0213 502 — Brussels,
• Ep0213 501 — Edegem,
• Ep0213 303 — Bielefeld,
• Ep0213 202 — Florence,
• Ep0213 203 — Genova,
• Ep0213 201 — Roma,
• Ep0213 204 — Roma,
• Ep0213 403 — Glasgow,
• Ep0213 401 — London,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Dravet Syndrome

• An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome — San Francisco, California
• A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome — Birmingham, Alabama
• The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project — Houston, Texas
• ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome — Ann Arbor, Michigan
• GABA Biomarkers in Dravet Syndrome — Fort Worth, Texas

Explore by condition: All Dravet Syndrome clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.